Month: November 2022

Yuan, Zaifeng; Zhu, Chunyu; Ma, Zhixian; Xia, Chengfeng published an article in 2018, the title of the article was Copper-catalyzed amination of an α-C(sp3)-H bond in inactivated ethers to synthesize α-aminonitriles.Quality Control of Methyl N-Methylanthranilate And the article contains the following content:

A copper-catalyzed functionalization of inert cyclic ethers was developed to provide α-aminonitriles via a cascade oxidation/amination/ring-opening/cyanation reaction. A series of highly versatile α-aminonitriles were obtained from primary or secondary anilines, and heterocyclic and aliphatic amines with high yields. This process features excellent functional group tolerance, a broad substrate scope, and high activity under ambient conditions. The experimental process involved the reaction of Methyl N-Methylanthranilate(cas: 85-91-6).Quality Control of Methyl N-Methylanthranilate

The Article related to aminonitrile preparation, ether amine cyanide amination copper catalyst, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Nitriles, Isonitriles, and Acyl Cyanides and other aspects.Quality Control of Methyl N-Methylanthranilate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Li, Yan-An; Yang, Song; Liu, Qi-Kui; Chen, Gong-Jun; Ma, Jian-Ping; Dong, Yu-Bin published an article in 2016, the title of the article was Pd(0)@UiO-68-AP: chelation-directed bifunctional heterogeneous catalyst for stepwise organic transformations.SDS of cas: 1312703-30-2 And the article contains the following content:

A bifunctional heterogeneous catalyst Pd(0)@UiO-68-AP based on a chelation-directed post-synthetic approach is reported. It exhibits typical heterogeneous catalytic behavior and can promote benzyl alc. oxidation-Knoevenagel condensation in a stepwise way. The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).SDS of cas: 1312703-30-2

The Article related to nanoparticle palladium zirconium uio catalyst preparation knoevenagel reaction oxidation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Nitriles, Isonitriles, and Acyl Cyanides and other aspects.SDS of cas: 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Yao, Shu-Feng; Cai, Zhao-Sheng; Huang, Xu-Juan; Song, Lan-Xuan published an article in 2020, the title of the article was Preparation of salicylic nitrile through direct catalytic dehydration of salicylamide with immobilized phosphoric acid as catalyst.Formula: C13H10O3 And the article contains the following content:

Salicylic nitrile was prepared through direct catalytic dehydration of salicylamide under high temperature using immobilized phosphoric acid as catalyst. The catalytic performances of different catalysts were evaluated according to the analytic results of GC-MS, and the feasibility about the preparation of salicylic nitrile by direct catalytic dehydration of salicylamide was investigated according to the composition of product determinated by GC anal. (area nomalization). Exptl. results indicated the comprehensive property of silica gel supported phosphoric acid was the best one among all of the catalysts utilized in this study. When the temperature of catalyst bed was 480 ± 10° and silica gel supported phosphoric acid was utilized as catalyst, the conversion ratio of salicylamide was 88.79%, the selectivity to salicylic nitrile was 97.97% and the yields of salicylic nitrile could up to 86.99%. Meanwhile, the exptl. results showed the increase of temperature of catalyst bed could result in the increase of the conversation of salicylamide, but much more byproduct could be formed when the temperature of catalyst bed was too high. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Formula: C13H10O3

The Article related to salicylamide immobilize phosphoric acid catalyst direct dehydration, salicylic nitrile preparation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Nitriles, Isonitriles, and Acyl Cyanides and other aspects.Formula: C13H10O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Yuan, Zaifeng; Li, Na; Zhu, Chunyu; Xia, Chengfeng published an article in 2018, the title of the article was Copper-catalyzed synthesis of α-amino nitriles through methyl transfer from DMF to aromatic amines.Application of 85-91-6 And the article contains the following content:

Synthesis of α-amino nitriles RR1NCH2CN [R = C6H5, 4-ClC6H4, 1-naphthyl, etc.; R1 = CH3, C2H5, c-C6H11, etc.] and α-amino nitriles, e.g., I via copper-catalyzed activation of C(sp3)-H bonds of DMF at room temperature, which resulted in Me transfer to aromatic amines followed by cyanation was described. This process featured excellent functional group tolerance, broad substrate scope and high activity under ambient conditions. The experimental process involved the reaction of Methyl N-Methylanthranilate(cas: 85-91-6).Application of 85-91-6

The Article related to alpha amino nitrile preparation, secondary aromatic amine dimethyl formamide cyanation copper catalyst, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Nitriles, Isonitriles, and Acyl Cyanides and other aspects.Application of 85-91-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 1, 2011, Noguchi, Toshiya; Ushiyama, Fumihito; Horikiri, Hiromasa; Yamamoto, Keiko; Ono, Naoya; Takayama, Tetsuo; Kamiyama, Tomoko published a patent.Product Details of 1198284-94-4 The title of the patent was Preparation of heterocyclic compounds or salts thereof for use as antibacterial agents. And the patent contained the following:

Disclosed is a medicament having a strong antibacterial activity against Gram-pos. bacteria, Gram-neg. bacteria, and resistant bacteria. A compound represented by formula I [a bond containing dotted line and connecting X2 to Y1 represents single bond or double bond; Z1-6 = N, CR; R = H, (halo)alkoxy, OH, halogen, (halo)alkyl, cycloalkyl, CN, NO2, etc.; X1 = (oxo-containing) C1-4 alkylene; X2 = bonding hand, CH; Y1 = spirocyclic group; X3 = C1-4 alkylene, NR'(CH2)m, SOn, bonding hand; R’ = H, C1-6 alkyl; m, n = 0, 1, 2; R1 = C3-6 cycloalkyl, C3-6 cycloalkenyl, aryl, heterocyclic group] or a salt thereof is useful as an antibacterial agent. Thus, compound II was synthesized through a multistep process and showed antibacterial activity against Staphylococcus aureus (MIC 0.03). The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Product Details of 1198284-94-4

The Article related to heterocyclic antibacterial agent preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 1198284-94-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 25, 2019, Zhang, Xingxian published a patent.Reference of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate The title of the patent was Compound for targeted ubiquitination degradation of EGFR protein and its pharmaceutical composition and application. And the patent contained the following:

Title compounds I [wherein A = (CH2CH2O)nCH2 or (CH)n, n is 1 to 6; B = (CH2)m, m is 1 or 2], and their pharmaceutically acceptable salts thereof, were prepared as EGFR inhibitors, useful in the treatment of cancer (breast cancer, colon cancer, prostate cancer, etc.). Thus, the invention compound I [A = (CH2)3; B = CH2] was prepared and gave PC9 inhibition IC50 value of 0.8444 μM. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Reference of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate

The Article related to heteroaryl antitumor egfr inhibitor preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Reference of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 16, 2009, Metzger, Axel; Qin, Lan-Ying; Cole, Andrew G.; Saionz, Kurt W.; Brescia, Marc-Raleigh; Gstach, Hubert; Wareing, James R.; Zimmermann, Juerg; Brill, Wolfgang K.-D.; Baldwin, John J.; Dolle, Roland E.; Henderson, Ian published an article.Product Details of 53838-27-0 The title of the article was Combined solution-phase and solid-phase synthesis of 2-amino-7,8-dihydropteridin-6(5H)-ones. And the article contained the following:

An efficient and general synthesis of substituted 2-amino-7,8-dihydropteridin-6(5H)-ones I [R1 = i-Bu, MeOCH2CH2, Ph, 3,4-Cl2C6H3, PhCH2CH2; R2 = Me, HOCH2, HO2CCH2CH2, H2N(CH2)4, 4-HOC6H4CH2; R3 = Ph, 4-ClC6H4, 3-pyridyl, etc.] using a combination of solution-phase and solid-phase chem. is described. Solution-phase chem. was used to produce two pyrimidine regioisomers that were separated by flash column chromatog. Utilizing the desired regioisomer II, solid-phase chem. was used to effect the rapid construction of the substituted 2-amino-7,8-dihydropteridin-6(5H)-one system in high overall yield and purity. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Product Details of 53838-27-0

The Article related to pteridinone amino dihydro solution solid phase synthesis, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 18, 2008, Mochizuki, Akiyoshi; Kishida, Masamichi; Kanno, Hideyuki published a patent.Recommanded Product: Ethyl 3-fluoro-2-methylbenzoate The title of the patent was Preparation of diamide derivatives as FXa inhibiting antithrombotics. And the patent contained the following:

The title compounds I [ring A = benzene ring, pyridine ring, pyrimidine ring, etc.; R1 = H, halo, alkyl, etc.; R2 = H, carboxy, carbamoyl, etc.; T1 = N(R3)CO; R3 = H, alkyl; T2 = (CH2)mCONH; m = 1 or 2; Q1 = cyclohexyl, morpholinyl, pyrrolidinyl, etc.; Q2 = single bond, 1,4-phenylene, 1,4-cyclohexylene, etc.; Q3 = (un)substituted Ph, thienyl, pyridyl, etc.] are prepared Thus, 4-[4-(2-([(5-chlorothiophene-2-carbonyl)amino]methyl]phenylcarbamoyl)phenyl)-3-oxopiperazine-1-carboxylic acid tert-Bu ester was prepared from N-(2-aminobenzyl)-5-chlorothiophene-2-carboxamide and 4-(2-[N-tert-butoxycarbonyl-N-(carboxymethyl)amino]ethylamino)benzoic acid. Compounds of this invention showed IC50 values of 1.1 nM to 8.8 nM against human FXa. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Recommanded Product: Ethyl 3-fluoro-2-methylbenzoate

The Article related to amide derivative preparation fxa inhibitor antithrombotic, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: Ethyl 3-fluoro-2-methylbenzoate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 17, 2022, Chen, Xiangyang; Pang, Yucheng published a patent.Electric Literature of 29704-38-9 The title of the patent was Pyridazine-3-carboxamide compound, its preparation and application in medicine. And the patent contained the following:

Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof. In particular, disclosed in the present invention are a compound as represented by general formula I and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing Janus kinase-mediated related diseases, in particular autoimmune diseases, inflammatory diseases and cancers, by means of using the compound or the pharmaceutically acceptable salt thereof, and a method for preparing the compound or the pharmaceutically acceptable salt thereof. Each substituent of general formula I has the same definition as that in the description. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Electric Literature of 29704-38-9

The Article related to pyridazine carboxamide preparation janus kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 29704-38-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 21, 2020, Chen, Xiangyang; Pang, Yucheng published a patent.Synthetic Route of 29704-38-9 The title of the patent was Pyridazine-3-carboxamide compound, its preparation and application in medicine. And the patent contained the following:

The invention relates to pyridazine-3-carboxamide compound of formula I as Janus Kinase inhibitor, its preparation and application for treatment of Janus Kinase-mediated diseases. Compounds I, wherein Z is N or CR1; ring A is substituted C6-10 aromatic ring or 5-10-membered aromatic hetero-ring; L is a bond or substituted C1-6 alkylene; R is H, halogen, cyano, SF5, etc.; R1 is H, halo, CN, etc.; Ra, Rb, Rc , Rd and Re are independently H, halo, CN, etc.; their pharmaceutically acceptable salts, prodrug, isomers or mixtures, are claimed. The inventive compound is capable of inhibiting or controlling Janus kinase, especially tyrosine kinase 2, and can be applied to the prevention and treatment of Janus kinase-mediated diseases, especially autoimmune disease, inflammatory disease and cancer. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Synthetic Route of 29704-38-9

The Article related to pyridazine carboxamide preparation janus kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 29704-38-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics